Astellas Pharma (Germany) Performance

YPH Stock  EUR 9.67  0.03  0.31%   
The firm shows a Beta (market volatility) of -0.0518, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Astellas Pharma are expected to decrease at a much lower rate. During the bear market, Astellas Pharma is likely to outperform the market. At this point, Astellas Pharma has a negative expected return of -0.21%. Please make sure to confirm Astellas Pharma's daily balance of power, as well as the relationship between the day typical price and relative strength index , to decide if Astellas Pharma performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Astellas Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Begin Period Cash Flow326.1 B
Free Cash Flow181 B
  

Astellas Pharma Relative Risk vs. Return Landscape

If you would invest  1,116  in Astellas Pharma on August 27, 2024 and sell it today you would lose (149.00) from holding Astellas Pharma or give up 13.35% of portfolio value over 90 days. Astellas Pharma is producing return of less than zero assuming 1.0234% volatility of returns over the 90 days investment horizon. Simply put, 9% of all stocks have less volatile historical return distribution than Astellas Pharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days trading horizon Astellas Pharma is expected to under-perform the market. In addition to that, the company is 1.33 times more volatile than its market benchmark. It trades about -0.21 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.15 per unit of volatility.

Astellas Pharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Astellas Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Astellas Pharma, and traders can use it to determine the average amount a Astellas Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.2101

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsYPH

Estimated Market Risk

 1.02
  actual daily
9
91% of assets are more volatile

Expected Return

 -0.21
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.21
  actual daily
0
Most of other assets perform better
Based on monthly moving average Astellas Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Astellas Pharma by adding Astellas Pharma to a well-diversified portfolio.

Astellas Pharma Fundamentals Growth

Astellas Stock prices reflect investors' perceptions of the future prospects and financial health of Astellas Pharma, and Astellas Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Astellas Stock performance.

About Astellas Pharma Performance

Assessing Astellas Pharma's fundamental ratios provides investors with valuable insights into Astellas Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Astellas Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.

Things to note about Astellas Pharma performance evaluation

Checking the ongoing alerts about Astellas Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Astellas Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Astellas Pharma generated a negative expected return over the last 90 days
Evaluating Astellas Pharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Astellas Pharma's stock performance include:
  • Analyzing Astellas Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Astellas Pharma's stock is overvalued or undervalued compared to its peers.
  • Examining Astellas Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Astellas Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Astellas Pharma's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Astellas Pharma's stock. These opinions can provide insight into Astellas Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Astellas Pharma's stock performance is not an exact science, and many factors can impact Astellas Pharma's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Astellas Stock Analysis

When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.